<DOC>
	<DOCNO>NCT02171598</DOCNO>
	<brief_summary>The primary objective study ( Main Part 2 ) investigate whether extent combination multiple oral dos ( steady state condition ) 75 mg clopidogrel q.d . ( load dose 300 mg ) multiple dose 150 mg dabigatran etexilate b.i.d . steady state affect pharmacokinetic pharmacodynamic parameter dabigatran etexilate clopidogrel . The objective preceding Pilot Part 1 study explore effect single dose 300 mg clopidogrel administer multiple dos 75 mg 150 mg dabigatran reach steady state , regard safety well pharmacokinetic pharmacodynamic parameter . The Main Part 3 study moreover compare intra-individually effect single dose 600 mg clopidogrel dose , 600 mg clopidogrel , give additionally multiple dos 150 mg dabigatran steady state condition respect safety pharmacokinetic pharmacodynamic parameter .</brief_summary>
	<brief_title>Investigation Impact Concomitant Use Multiple Doses Clopidogrel With Multiple Doses Dabigatran Etexilate Pharmacokinetic Pharmacodynamic Parameters Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>1 . Healthy male subject accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , body temperature , 12lead electrocardiogram , clinical laboratory test 2 . Age ≥18 Age ≤40 year 3 . Body mass index ( BMI ) ≥18.5 ≤29.9 kg/m2 ( Body Mass Index ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation . 1 . Any gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Subjects investigator 's judgement perceive increase risk bleeding , example : Hemorrhagic disorder bleed diathesis Occult blood faeces haematuria Trauma surgery within last month long excessive risk bleed persists event , plan surgery trial participation History arteriovenous malformation aneurysm History gastroduodenal ulcer disease , gastrointestinal haemorrhage haemorrhoid History intracranial , intraocular , spinal , retroperitoneal , atraumatic intraarticular bleeding Use drug may interfere haemostasis trial conduct ( e.g.acetyl salicylic acid nonsteroidal antiinflammatory drug ) 3 . Relevant surgery gastrointestinal tract 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . History relevant orthostatic hypotension , faint spell blackouts 6 . Chronic relevant acute infection 7 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 8 . Intake medication within four week first dose 9 . Use drug might reasonably influence result trial base knowledge time protocol preparation within four week prior administration trial , especially inhibitor inducer Pgp , CYP3A4 CYP2C9 CYP2C19 10 . Intake medication , influence blood clotting , i.e. , acetylsalicylic acid , nonsteroidal antirheumatic drug , cumarin etc . within 10 day prior administration trial 11 . Participation another trial investigational drug within one month prior administration trial 12 . Alcohol abuse ( 60 g/day regular basis ) 13 . Drug abuse 14 . Within 5 day study medication intake grapefruit , grapefruit juice , product contain grapefruit juice , Seville oranges , garlic supplement , St. John 's Worth 15 . Blood donation ( 100 mL within four week prior administration ) 16 . Excessive physical activity ( within one week prior administration trial ) 17 . Any laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen study centre 19 . Male subject agree minimise risk female partner become pregnant first dose day 3 month completion study . Acceptable method contraception comprise barrier contraception medically accept contraceptive method female partner ( intrauterine device spermicide , hormonal contraceptive since least two month )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>